Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

NCT05013554 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Malignant
Breast Cancer
Lung Neoplasm Malignant
Gastric Cancer
Neoplasm

Interventions

DRUG: SAR443216 IV
DRUG: SAR443216 SC

Sponsor

Sanofi